Telix Pharmaceuticals Ltd. has entered an agreement to acquire radioisotope production technology firm ARTMS Inc., its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
 
ARTMS, based in Burnaby, British Columbia, Canada, is a privately held, venture-backed company, which specializes in the physics, chemistry and materials science of cyclotron-produced radionuclides. A spin-out company from TRIUMF, Canada’s particle accelerator center, ARTMS is a commercial-stage company and its technology is used by major manufacturing networks to optimize production of a range of medical radioisotopes.
 
The acquisition is expected to further enhance the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of control and security over each of the company’s diagnostic isotopes.
 
ARTMS’ core technology platform is based on the QUANTM Irradiation System (QIS), a complete cyclotron-based isotope production system designed to support high efficiency and cost-effective production of commercially important medical isotopes including zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu).
 
Additionally, ARTMS’ portfolio of advanced cyclotron technologies will have immediate application and differentiation in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At). 

As part of the acquisition, Telix will also acquire ARTMS’s production facility and clean rooms, located in Burnaby. Telix expects to continue to operate and expand ARTMS’ R&D and production capabilities at the Burnaby location to support in-house and customer needs.